References
- Firoz M, Graber M. Bioavailability of US commercial magnesium preparations. Magnes Res. 2001;14:257–262.
- Sun-Edelstein C, Mauskop A. Role of magnesium in the pathogenesis and treatment of migraine. Expert Rev Neurother. 2009;9:369–379.
- FDA. Blood Serum Chemistry – Normal Values. Investigations Operations Manual (IOM). 2015. Appendix C: 443. Available from: http://www.fda.gov/downloads/ICECI/Inspections/IOM/UCM135835.pdf
- Friedberg RC, Souers R, Wagar EA, et al. The origin of reference intervals. Arch Pathol Lab Med. 2007;131:348–357.
- Lewis JL. III. Overview of disorders of magnesium concentration. Merck Manuals Professional Edition. 2015. Available from: http://www.merck.com/mmpe/sec12/ch156/ch156i.html#sec12-ch156-ch156i-956
- Bringhurst FR, Demay MB, Krane SM, et al. Bone and mineral metabolism in health and disease. In: Kasper, D, editor. Harrison’s principles of internal medicine. 16th ed. New York (NY): McGraw-Hill; 2005. p. 2238–2249.
- Douban S, Brodsky MA, Whang DD, et al. Significance of magnesium in congestive heart failure. Am Heart J. 1996;132:664–671.
- Tosiello L. Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch Intern Med. 1996;156:1143–1148.
- Mauskop A, Altura BT, Cracco RQ, et al. Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. Clin Sci. 1995;89:633–636.
- Whang R, Oel TO, Aikawa JK, et al. Predictors of clinical hypomagnesemia. Hypokalemia, hypophosphatemia, hyponatremia, and hypocalcemia. Arch Intern Med. 1984;144:1794–1796.
- Dyckner T, Wester PO. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusions in patients on diuretic treatment. Am Heart J. 1979;97:12–18.
- Kohvakka A, Luurila O, Gordin A, et al. Comparison of potassium alone and potassium-magnesium supplementation in patients with heart failure using hydrochlorothiazide. Magnesium. 1989;8:71–76.
- Whang R, Flink EB, Dyckner T, et al. Magnesium depletion as a cause of refractory potassium repletion. Arch Intern Med. 1985;145:1686–1689.
- Ranade VV, Somberg JC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther. 2001;8:345–357.
- Walker AF, Marakis G, Christie S, et al. Mg citrate found more bioavailable than other Mg preparations in a randomized, double blind study. Magnesium Res. 2003;16:83–191.
- Rylander R. Bioavailability of magnesium salts – a review. J Pharm Nutr Sci. 2014;4:57–59.
- Rasmussen HS, Cintin C, Aurup P, et al. The effect of intravenous magnesium therapy on serum and urine levels of potassium, calcium, and sodium in patients with ischemic heart disease, with and without acute myocardial infarction. Arch Intern Med. 1988;148:1801–1805.
- National Institutes of Health. Magnesium. Office of Dietary Supplements. 2013. Available from: https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
- Institute of Medicine. Food and Nutrition Board. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Washington, DC: National Academy Press. 1997. Available from: http://www.nap.edu/read/5776/chapter/1
- Siener R, Jahnen A, Hesse A. Bioavailability of magnesium from different pharmaceutical formulations. Urol Res. 2011;39:123–127.
- Schuchardt JP, Hahn A. Intestinal absorption and factors influencing bioavailability of magnesium – an update. Curr Nutr Food Sci. 2017;13:260–278.
- Bohn T. Dietary factors influencing magnesium absorption in humans. CNF. 2008;4:53–72.